Hidradenitis Suppurativa: New Therapeutic Targets. Some May Surprise You!

Be prepared for anything after this session, which will discuss recent advances in hidradenitis suppurativa treatments. Biologic therapies and small-molecule drugs have expanded treatment options by targeting key components of the disease's immunopathogenesis. Biologics, including TNF-α inhibitors and interleukin-targeting agents, have demonstrated efficacy in reducing inflammation, abscess formation, and disease progression, while improving quality of life. Meanwhile, small-molecule therapies offer advantages such as oral delivery, novel intracellular targets, and immune modulation. Ongoing research is optimizing the use of these agents, exploring their long-term outcomes, and investigating combination approaches.